Innovaccer Receives Frost & Sullivan’s 2026 United States New Product Innovation Recognition for Excellence in AI-Driven Patient Access Solutions
The recognition highlights Innovaccer's innovation leadership in transforming patient access through omnichannel, AI-powered engagement and workflow unification. SAN ANTONIO, March 3, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Innovaccer has received the 2026 United States New Product Innovation Recognition in the United States Patient Access Solutions Industry for its outstanding achievements in innovation, strategy execution,...
The Sigourney Award-2026 Now Accepting Applications for Psychoanalytic Innovation
International Prize Honors Trailblazing Work Advancing Psychoanalytic Thought and Principles — Cash Award and Global Recognition SAN FRANCISCO, March 2, 2026 /PRNewswire/ -- The Sigourney Award Trust welcomes applications for The Sigourney Award-2026 from individuals, teams, and organizations worldwide whose work has advanced psychoanalytic thinking and principles. Applications are open through July 31, 2026,...
XellSmart Receives Fourth Consecutive US FDA & China NMPA IND Clearance for MSA-P iPSC-derived Cell Therapy
SUZHOU, China, March 2, 2026 /PRNewswire/ -- In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its independently developed, off-the-shelf, allogeneic, universal, iPSC-derived, subtype-specific neuron progenitor cell therapy targeting Multiple System Atrophy- Parkinsonian Type (MSA-P). This joins the previous three consecutive FDA-NMPA registrational...
ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease. SAN FRANCISCO and SHANGHAI, March 2, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company pioneering AI-driven RNA-modulating small molecules to treat rare and genetic diseases, today announced a pivotal clinical and dual regulatory milestone: the first participant has been dosed in the First-in-Human (FIH)...
Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®
PHILADELPHIA, March 2, 2026 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and autoimmune diseases, proudly announced positive topline results from a Phase II clinical trial of its next-generation anti-IgE antibody, LP-003, with a head-to-head comparison with Xolair® (Omalizumab). The data was presented as a late-breaking poster at the 2026 AAAAI Annual...
Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit
LEHI, Utah, March 2, 2026 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today announced that it will deliver a company presentation at the BIO Investment & Growth Summit. David Bearss, Ph.D., Chief Executive Officer of Halia Therapeutics, will present an overview of the company's strategy,...
The largest pharma show in Asia makes its return to Shanghai this June 2026
SHANGHAI, March 2, 2026 /PRNewswire/ -- CPHI & PMEC China 2026 is set to take place from 16 to 18 June 2026 at the Shanghai New International Expo Centre (SNIEC), building on its extremely successful run over the last few years. CPHI & PMEC China 2026 As the world's premier destination for pharmaceutical...
CooperVision Expands MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses Into Asia Pacific Region
Second Phase of Rollout Builds on Strong Momentum Across Europe and UK. ROCHESTER, N.Y., March 2, 2026 /PRNewswire/ -- CooperVision is continuing its global rollout of MyDay® MiSight® 1 day contact lenses with immediate availability in Australia and New Zealand, marking the myopia control product's first entry into the Asia Pacific...
ECR 2026: Esaote Group Introduces Breakthroughs in Ultrasound, MRI and Enterprise Imaging
The new MyLab™E85 GTS and MyLab™C30 GTS Edition ultrasound systems will be presented on Thursday, 5th March at 11.30 a.m. at the Esaote Booth GENOA, Italy, March 2, 2026 /PRNewswire/ -- Esaote Group, a leading Italian innovator in medical imaging – ultrasound, dedicated magnetic resonance and medical IT – attends European Congress of...
COLUMBIA ASIA HOSPITAL BUKIT JALIL LAUNCHES NEW CATH LAB TO STRENGTHEN HEART CARE SERVICES
The new cardiac catheterisation facility enables faster, minimally invasive treatment and improved access to specialist care, closer to home. KUALA LUMPUR, Malaysia, March 2, 2026 /PRNewswire/ -- Columbia Asia Hospital Bukit Jalil has officially launched its new Cardiac Catheterisation Laboratory (Cath Lab), marking a significant step forward in expanding access to advanced...
